Leukemia: New Treatment Approach Discovered

by Colleen Fleiss on  January 26, 2019 at 5:31 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

In BCR/ABL leukemia, STAT5B facilitates leukemogenesis. STAT5A and STAT5B are twins with different personalities. The study findings might help explain the high frequency of STAT5B mutations in hematopoietic tumors.

STAT5A and STAT5B: Not everything that looks the same is the same
Leukemia: New Treatment Approach Discovered
Leukemia: New Treatment Approach Discovered

But STAT5 actually consists of two genes: STAT5A and STAT5B. The two are very similar and, being more than 90 % identical, had been considered to be functionally equal. Research had therefore focused primarily on the function of STAT5A, as it had appeared to be of greater importance.

In their recently published study in the journal Leukemia, the researchers from Vetmeduni Vienna wanted to know for sure. Veronika Sexl from the Institute of Pharmacology and Toxicology at Vetmeduni Vienna was the director of the study: "In our previous studies, we always turned off both genes, as they are situated next to each other on the chromosome.

What is exciting is that in recent years cases have been found of patients with mutations that result in STAT5 activation and are assumed to drive disease. Surprisingly, these mutations were found at a much higher frequency in STAT5B than in STAT5A." This finding led the research team to ask: Why are mutations found in STAT5B and not in STAT5A? And why is overactivation of STAT5B "good" for the tumor cell?

STAT5B: Therapeutic approach: new, precision medicine strategies

The Vetmeduni Vienna research team probed these questions by investigating the different function of STAT5A and STAT5B in a mouse model and in human leukemia cells. The absence of STAT5A led to a decrease in cell survival and the formation of colonies of malignant cancer cells. Even more significant effects were observed in the absence of STAT5B. In the mouse model, loss of STAT5B increased interferon response and suppressed transformation. The opposite scenario was the case in patients with overactive STAT5B: the interferon response against tumor growth was suppressed, and transformation was enhanced.

According to the researchers, this may be of direct clinical relevance for patients, as a better understanding of the complex role of STAT5B could enable the development of precision medicine strategies to treat disease.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive